Objective:

To analyze the clinical impact with the early use of Oxygen Therapy with High Flow Nasal Cannula (HFNC), in patients with acute respiratory failure due to COVID-19, without indication for immediate Intubation.

Materials and methods:

Descriptive, observational and prospective study.

Results:

Of 87 patients admitted to the ICU with Respiratory Failure due to COVID-19, 19 cases met inclusion criteria, male 57.89% (n=11) and female 42.1% (n=8), age 34.8 (±6.6). ) years, lung involvement measured by scale (CO-RADS) with a predominance of category 3 in 42.1% (n=8), category 2 in 21.05% (n=4), indication for initiation of oxygen therapy by HFNC was due to Mild ARDS/ Moderate 73.6% (n=14), Severe ARDS with Severe Pneumonia due to COVID-19 26.3% (n=5), The time of use of HFNC was 96 h (±28), with a stay in the ICU of 12 ( ±2) days and hospital stay 13 (±1), evaluating respiratory improvement, corroborated (ROX INDEX (iROX), failure value ≤ 2.75) recording an i-ROX: 3.42 (±1.2) initial, and elevation up to 5.8 (±0.9) (p = 0.05) at 72h in 15 patients (78.9%); recording failure in 4 (21.1%) with CNAF support, obtaining i-ROX 2.2 at 12 hours, proceeding to be intubated between 24 hours and 72 hours. Demonstrating the signíficant increase in (í-ROX), improvement in respiratory work in 78.9% (n=15) vs failure of the HFNC device in 4 who were intubated 21.1% (n=4), leading to death.

Conclusión:

The early use of the HFNC device in COVID-19 pneumonia with mild and moderate respiratory failure would be a useful and beneficial alternative as an initial alternative therapy.

        · resumen en Español     · texto en Español     · Español ( pdf )